What the New CDC Hepatitis B Recommendation Means for the Birth Dose.

In December 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to move away from its long‑standing recommendation for universal hepatitis B vaccination at birth. For the first time since 1991, parents of infants born to mothers who test negative for hepatitis B are now being encouraged to engage in “individual-based decision making” about whether to give the birth dose or delay vaccination until later in infancy.

This shift has generated confusion and concern among clinicians, parents, and public health leaders. To understand why, it helps to revisit how hepatitis B is transmitted, why newborn vaccination has mattered so much, and what’s at stake with this policy change.

Why Universal Newborn Hepatitis B Vaccination Matters

Before 1991, hepatitis B vaccination in the U.S. was risk-based, largely targeting infants born to hepatitis B-positive mothers. That approach made little impact on childhood infections. Many infants acquired hepatitis B outside of high-risk categories, often through household or early childhood exposure.

Once universal newborn vaccination began in 1991, the results were dramatic. Rates of hepatitis B infection among children and adolescents dropped by approximately 99%, preventing tens of thousands of cases of chronic liver disease, cirrhosis, liver cancer, and premature death. Over more than three decades, no new safety or efficacy concerns emerged.

Universal vaccination worked because it protected infants during a uniquely vulnerable window, before exposures could occur and before gaps in testing or follow-up had consequences.

How Babies Get Hepatitis B (and Why Risk Isn’t Always Obvious)

Hepatitis B virus (HBV) is highly infectious and can be transmitted through very small amounts of infected blood or body fluids. For infants, transmission can occur:

• Perinatally, or vertically, from parent to child around the time of birth.

• Horizontally, through early childhood exposure, often from household contacts or caregivers who may not know they are infected.

HBV can survive on surfaces for at least seven days and can be transmitted without visible blood. Toothbrushes, washcloths, kisses from relatives with cracked lips, shared toys, or small skin breaks are all potential routes.

This matters because not all exposure risk is known or predictable, and not all infections are identified during pregnancy.

Why Infection in Infancy is Different

Hepatitis B infection looks very different depending on the age at which it’s acquired:

• Up to 90% of infants infected in the first year of life go on to develop chronic hepatitis B

• By contrast, only 5–10% of adults with acute infection develop chronic disease

• Chronic HBV infection can lead to cirrhosis, hepatocellular carcinoma, and premature death

Most infected infants are completely asymptomatic, making diagnosis unlikely unless testing is performed deliberately. In short, early infection often leads to lifelong disease, which is precisely why early protection matters.

Prenatal Screening Is Important, but Not Foolproof

American College of Obstetrics and Gynecology (ACOG) and Society for Maternal Fetal Medicine (SMFM) continue to recommend universal hepatitis B screening early in pregnancy with a triple panel — surface antigen, surface antibody, and core antibody — replacing the old surface-antigen-only approach, with additional testing or rescreening for those with risk factors. However, in real-world practice:

• Screening often happens once, early in pregnancy, and often still with only hepatitis B surface antigen.

• Risk factors may emerge later and are not always rescreened.

• Repeat testing at delivery is not routine unless someone is considered “high risk,” which is fraught with potential bias.

The assumption that a negative first-trimester test equals no risk at birth overlooks the reality that infection can occur at any point during pregnancy, and that exposure risk is dynamic.

Universal newborn vaccination has historically acted as a safety net for these very gaps.

What Changed in the New ACIP Recommendation?

Under the updated guidance:

• Infants born to mothers who are hepatitis B–positive or whose status is unknown should still receive the birth dose

• Infants born to mothers who test negative may delay vaccination until 1–2 months of age, based on shared decision-making

ACIP also suggested that parents and clinicians could consider antibody testing later in infancy to assess protection, a recommendation that is not evidence-based and is not used for other routine vaccines.

Notably, there is no new data suggesting decreased vaccine safety, reduced effectiveness, or lower infant risk compared to prior decades.

Why Many Experts Are Concerned

Major medical organizations, including the American Academy of Pediatrics(AAP), American Academy of Family Physicians (AAFP),World Health Organization (WHO), ACOG, SMFM, and public health experts, continue to recommend universal birth-dose vaccination.

Key concerns include:

• Overreliance on perfect prenatal testing and follow-up

• Increased risk of missed or delayed vaccination

• Greater vulnerability to household and community exposure

• Added complexity that makes errors more likely

• Erosion of a public health success story built over 35 years

Modeling suggests that even small declines in newborn vaccination rates could result in hundreds of additional children developing chronic hepatitis B over the coming decade, children who otherwise would have been protected.

The Vaccine: Safe, Effective, and Remarkably Successful

The hepatitis B vaccine has been used for decades and is one of the most studied vaccines worldwide:

• 95% of healthy infants develop immunity after completing the series

• Serious adverse events are exceedingly rare

• Anaphylaxis occurs in approximately 1 in 600,000 doses

• No association with neonatal sepsis, neurologic injury, or death

In other words: the science has not changed.

Talking With Families: Prenatal and Postnatal Conversations

These conversations work best when they happen early and often:

• Introduce hepatitis B vaccination prenatally, when trust and continuity already exist

• Explain that the birth dose is about protecting infants during a vulnerable window, not about parental behavior

• If hesitancy arises, lead with curiosity, not correction

• Be prepared to address common myths and highlight the vaccine’s long safety record

• Normalize ongoing dialogue rather than forcing one-time decisions

Personal experience and clear explanations often go a long way.

What Clinicians Should Do

Hepatitis B vaccination remains one of the most effective public health interventions in modern medicine. Universal newborn vaccination has almost eliminated childhood HBV infection in the U.S., protecting infants during a period when they are most vulnerable and least able to be monitored for risk.

While federal recommendations may evolve, the biology of hepatitis B has not changed, nor has the vaccine’s safety or effectiveness. As clinicians, our role is to advocate for evidence-based care, communicate clearly, and ensure families are supported in making informed decisions, especially when the stakes are lifelong.